Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
09/2010
09/15/2010CN101835792A FOXM1 peptide and medicinal agent comprising the same
09/15/2010CN101835490A Lox and l0xl2 inhibitors and uses thereof
09/15/2010CN101835489A IL-18 receptor antigen binding proteins
09/15/2010CN101835488A Thermal inactivation of rotavirus
09/15/2010CN101835487A Composition and methods of making and using influenza proteins
09/15/2010CN101835482A Polymeric linkers containing pyridyl disulfide moieties
09/15/2010CN101831480A Staphylococcal enterotoxin C3 preparation, formulation, dosage and application thereof
09/15/2010CN101831434A Anti-human CD45RA rat immune globulin variable region gene and application
09/15/2010CN101831411A Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
09/15/2010CN101830985A Recombination protein of enterohemorrhagic Escherichia coli O157:H7Tir and Tccp
09/15/2010CN101830974A Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use therof
09/15/2010CN101830968A Bursa of Fabricius heptapeptide with immune regulation effect
09/15/2010CN101829337A Immune composition aiming at Neisseria meningitidis
09/15/2010CN101829325A Pharmaceutical composition for treatment of diseases caused by IL-6 production
09/15/2010CN101829324A Treatment of intermediate-and high-grade non-hodgkins lymphoma with anti-CD20 antibody
09/15/2010CN101829323A Poultry oil emulsion vaccine and preparation method thereof
09/15/2010CN101829322A Application of superantigen fusion protein cell factor in preparation of anti-solid tumor medicament
09/15/2010CN101829321A Vaccine for preventing red head disease of Pseudobagrus fulvidraco
09/15/2010CN101298615B Novel anti-plasmodium falciparum epitope and vaccine containing the same
09/15/2010CN101181636B Compound vaccine composition for preventing and controlling human viral infection, compound vaccine vaginal mist and uses thereof
09/15/2010CN101180068B Use of polysaccharides extracted from dendrobium in preparing medicine for treating autoimmune disease uveitis
09/14/2010US7795494 Transgenic animals capable of generating antibodies, e.g., human monoclonal antibodies, specific for the product of a gene of interest
09/14/2010US7795413 Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
09/14/2010US7795406 Agent for treating leishmania infections
09/14/2010US7795391 Protein showing enhanced expression in cancer cells
09/14/2010US7795224 Tumor associated antigen peptides and use of same as anti-tumor vaccines
09/14/2010US7795211 Overexpression of protease hepsin; induce immunology response; inoculation with hepsin peptide; monitoring immunotherapy
09/14/2010US7795017 plasmid constructs useful for the delivery of DNA vaccines; having a transcription cassette capable of directing the expression of a vaccine nucleic acid insert encoding immunogens derived from any pathogen, including fungi, bacteria and viruses
09/14/2010US7794998 vectors and vaccines for use in humans against infection and disease; human T-lymphotropic virus
09/14/2010US7794975 Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide
09/14/2010US7794756 Methods of using antibodies to VEGF-C
09/14/2010US7794736 Canine Leishmania vaccine
09/14/2010US7794735 Pathogen for bacterial poultry disease
09/14/2010US7794734 for immunizing cattle against infection from Mannheimia haemolytica; vaccine having purified recombinant PlpE outer membrane protein of Mannheimia with adjuvant; veterinary medicine
09/14/2010US7794733 Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis, compositions containing same and methods of use thereof
09/14/2010US7794732 Anthrax compositions and methods of use and production
09/14/2010US7794731 Use of flagellin in the immunotherapy of Yersinia pestis
09/14/2010US7794730 Polyvalent attenuated live vaccine for preventing and curing vibriosis of cultivated fish
09/14/2010US7794729 Administering a Listeria vaccine with a strain expressing an antigen fused to a truncated LLO protein; cancer vaccines; anticarcinogenic agents
09/14/2010US7794728 Induction immunology response; vaccines
09/14/2010US7794727 Polyvalent chimeric OspC vaccinogen and diagnostic antigen
09/14/2010US7794726 based on a native version of the enzyme from E. corrodens and induces production of antibodies that inhibit the activity of the lysine decarboxylase enzyme in the oral cavity; comprising a substitution at a position corresponding to position 365 of SEQ ID NO:2
09/14/2010US7794725 Isolated peptides derived from human immunodeficiency virus types 1 and 2 containing fusion inhibitory domains
09/14/2010US7794724 Fish vaccine
09/14/2010US7794723 treatment or prophylaxis of cancer using proteins or peptides that elicit T cell mediated immunity; vaccination
09/14/2010US7794722 Natural killer T-cell agonists; vaccines; antigen presenting cells
09/14/2010US7794721 Multimeric immunoglobulin for use in prevention and treatment of viral and microorganismal infection
09/14/2010US7794720 isolating canine animal plasma; selecting a canine animal for a blood group that does not cause plasma transfusion reaction and/or haemolysis and using the plasma for immunization
09/14/2010US7794719 variable regions peptides for immunizing against amyloid plaque formation; biodrug for dementia, Alzheimer's disease, neuropathy, Down's syndrome, Creutzfeld Jacob disease, Parkinson's disease, amyotropic lateral sclerosis; neuroprotectants; hemostatic agent
09/14/2010US7794718 fusion protein comprising polypeptide with a human immunoglobulin (Ig) polypeptide; has an ability to bind CD80 or CD86 or an extracellular domain of either CD80 or CD86, and/or an ability to inhibit a T cell immune response
09/14/2010US7794717 Cytokine specific immunoglobulin for use in diagnosis, prevention and treatment ,of cell proliferative, inflammatory, allergic, respiratory, autoimmune and arthritic disorders
09/14/2010US7794716 Antibody composition and passive immunization against pregnancy-induced hypertension
09/14/2010US7794715 T-cell immune response cDNA 7 (TIRC7) antagonist; rheumatoid arthritis; comprising all three complementarity determining regions (CDRs) of the VH and all three complementarity determining regions (CDRs) of the VL variable regions
09/14/2010US7794714 Anti-peptide monoclonal antibodies (MAb's) specific for Exotic Newcastle Disease (END) are used for rapid diagnostic identification between poultry infected with vaccine strains of NDV (LaSota/B1) and END virus (ENDV)
09/14/2010US7794713 Administering an agent that interferes with S1P activity, preferably an antibody or an agent with first binding moiety that is specifically reactive S1P and a second binding moiety that is specifically reactive with a second molecule other than S1P; for human or veterinary use
09/14/2010US7794711 Agent for treating chondroma and chondrosarcoma
09/14/2010US7794710 Identifying a mammal with, or at risk of developing, cancer; cells of the cancer are identified as expressing B7-H1 molecules on their surfaces, and administering an agent that interferes with interaction between B7-H1 and t-cells
09/14/2010CA2478235C Protein purification
09/14/2010CA2409406C Qs-21 and il-12 as an adjuvant combination
09/14/2010CA2370393C Dna sequence, and recombinant production of a gramineae allergen
09/14/2010CA2343569C Mammalian transforming growth factor beta - 9
09/14/2010CA2290696C Immunopotentiating composition
09/14/2010CA2261345C Feline polynucleotide vaccine formula
09/14/2010CA2166406C Recombinant swinepox virus
09/14/2010CA2146693C Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
09/12/2010CA2658259A1 Dengue virus-like particle and uses thereof
09/10/2010WO2010102276A2 Humanized anti-cd19 antibody formulations
09/10/2010WO2010102251A2 Il-17 binding proteins
09/10/2010WO2010102244A1 Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
09/10/2010WO2010102140A1 Compositions comprising angiogenic factors and methods of use thereof
09/10/2010WO2010102112A2 Treatment of drug-related side effect and tissue damage by targeting the cd24-hmgb1-siglec10 axis
09/10/2010WO2010101750A2 Attenuated salmonella enterica serovar paratyphi a and uses thereof
09/10/2010WO2010101528A1 A biomarker and treatment for cancer
09/10/2010WO2010100878A1 Vangl1 peptides and vaccines including the same
09/10/2010WO2010100632A2 Chlamydia antigens
09/10/2010WO2010100383A1 Anti-rhesus d monoclonal antibody
09/10/2010WO2010100247A1 Novel therapy for anxiety
09/10/2010WO2010100056A2 Antibodies against a proliferating inducing ligand (april)
09/10/2010WO2010099960A2 Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essential consisting of vp3
09/10/2010WO2010099956A1 Cloning and recombinant production of vespula venom protease and methods of use thereof
09/10/2010WO2010099637A1 Methods for proliferation of antigen-specific t cells
09/10/2010WO2010099612A1 Antibodies and epitopes specific to misfolded prion protein
09/10/2010WO2010099580A1 Treatment of infection
09/10/2010WO2010066868A3 Anti-igf antibodies
09/10/2010WO2010065077A3 Antagonists of il-6 to prevent or treat thrombosis
09/10/2010WO2010053877A3 Mhc ii associated protein and uses thereof
09/10/2010WO2010053316A3 New use of sixth immunoglobulin-like domain of vcam-1
09/10/2010WO2010048446A3 Modulation of axon degeneration
09/10/2010WO2010036948A3 Dna vaccine against influenza virus and prime boost method
09/10/2010WO2010027499A9 Methods, compositions and vaccines relating to neisseria meningitidis antibodies
09/10/2010WO2007118986A8 Concentrate of immunoglobulins and f(ab)'2 and/or fab fragments specific of an arbovirus as medicine
09/10/2010CA2754618A1 Chlamydia antigens
09/10/2010CA2754533A1 Treatment of infection
09/10/2010CA2754335A1 Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essentially consisting of vp3
09/10/2010CA2754266A1 Humanized anti-cd19 antibody formulations
09/10/2010CA2753995A1 Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
09/10/2010CA2753991A1 Secreted ap2 and methods of inhibiting same
09/10/2010CA2753700A1 Anti-rhesus d monoclonal antibody
09/10/2010CA2753681A1 Vangl1 peptides and vaccines including the same
09/10/2010CA2753621A1 Antibodies and epitopes specific to misfolded prion protein
1 ... 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 ... 1823